Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

March 2017 | 92 pages | ID: M28D099466AEN
Black Swan Analysis limited

Abstracts

Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant diseases affecting the neuromuscular junction. The disorder is caused by auto-antibodies that target components of the post-synaptic muscle endplate. This includes antibodies that target acetylcholine receptors (AChR), muscle-specific kinase (MUSK) and lipoprotein release protein 4 (LRP4). Please note that this module does not cover congenital MG forms.

This report provides the current prevalent population for Myasthenia Gravis across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Denmark, Netherlands, Norway, Sweden, Estonia, Croatia, Poland, Russia, Greece, Turkey, Japan, China, South Korea, Argentina, Brazil, Mexico, India and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Myasthenia Gravis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

MG often co-occurs with other autoimmune conditions including:

• RA
• MS
• Ankylosing spondylitis
• Psoriasis
• Sjogren's syndrome
• Ulcerative colitis
• Crohn's disease
• Other forms of AI

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

REASON TO BUY

• Able to quantify patient populations in global Myasthenia Gravis market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Myasthenia Gravis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Myasthenia Gravis prevalent population.
• Identify sub-populations within Myasthenia Gravis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Myasthenia Gravis patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid Conditions/Features Associated with the Disease
Methodology for quantification of patient numbers
Top-line Prevalence for Myasthenia Gravis
Classification of Myasthenia Gravis Patients
  Serotype/Presence of Autoantibodies in Myasthenia Gravis
  Comorbidities and Symptoms of Myasthenia Gravis patients
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Figures

LIST OF FIGURES

MG at the neuromuscular junction

List Of Tables

LIST OF TABLES

Osserman criteria for severity staging of Myasthenia Gravis
Myasthenia Gravis Foundation of America criteria for severity staging
Prevalence of MG,total (000s)
Prevalence of MG, males (000s)
Prevalence of MG, females (000s)
MG patients by phenotype, total (000s)
MG patients by subtype, total (000s)
MG patients by severity, total (000s)
AChR seropositive MG, total (000s)
MUSK seropositive MG, total (000s)
LRP4 seropositive MG, total (000s)
MG patients with Thymoma, total (000s)
MG patients in Crisis, total (000s)
MG patients with Ptosis, total (000s)
MG patients with Dysphagia, total (000s)
MG patients with diplopia, total (000s)
MG patients with another autoimmune condition, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
USA Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Canada Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Canada Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
France Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
France Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Germany Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Germany Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Italy Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Italy Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Spain Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Spain Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
UK Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
UK Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Ireland Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Ireland Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Denmark Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Denmark Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Netherlands Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Netherlands Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Norway Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Norway Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Sweden Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Sweden Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Estonia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Estonia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Croatia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Croatia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Poland Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Poland Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Greece Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Greece Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Turkey Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Turkey Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Argentina Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Argentina Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Brazil Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Brazil Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Mexico Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Mexico Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Japan Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Japan Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
South Korea Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
South Korea Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
India Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
India Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Australia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Australia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
China Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
China Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)
Russia Prevalence of Myasthenia Gravis by 5-yr age cohort, males (000s)
Russia Prevalence of Myasthenia Gravis by 5-yr age cohort, females (000s)